344 related articles for article (PubMed ID: 22775210)
21. Identification of novel specific and general inhibitors of the three major human ATP-binding cassette transporters P-gp, BCRP and MRP2 among registered drugs.
Matsson P; Pedersen JM; Norinder U; Bergström CA; Artursson P
Pharm Res; 2009 Aug; 26(8):1816-31. PubMed ID: 19421845
[TBL] [Abstract][Full Text] [Related]
22. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter.
Ding PR; Tiwari AK; Ohnuma S; Lee JW; An X; Dai CL; Lu QS; Singh S; Yang DH; Talele TT; Ambudkar SV; Chen ZS
PLoS One; 2011 Apr; 6(4):e19329. PubMed ID: 21552528
[TBL] [Abstract][Full Text] [Related]
23. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
[TBL] [Abstract][Full Text] [Related]
24. Reversal of different drug-resistant phenotypes by an autocatalytic multitarget multiribozyme directed against the transcripts of the ABC transporters MDR1/P-gp, MRP2, and BCRP.
Kowalski P; Surowiak P; Lage H
Mol Ther; 2005 Apr; 11(4):508-22. PubMed ID: 15771954
[TBL] [Abstract][Full Text] [Related]
25. The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport.
Dahan A; Sabit H; Amidon GL
AAPS J; 2009 Jun; 11(2):205-13. PubMed ID: 19319690
[TBL] [Abstract][Full Text] [Related]
26. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
27. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
28. Potential role of ATP-binding cassette transporters in the intestinal transport of rhein.
Ye L; Lu L; Li Y; Zeng S; Yang X; Chen W; Feng Q; Liu W; Tang L; Liu Z
Food Chem Toxicol; 2013 Aug; 58():301-5. PubMed ID: 23665409
[TBL] [Abstract][Full Text] [Related]
29. Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance.
Kwatra D; Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK
Int J Pharm; 2010 Aug; 395(1-2):114-21. PubMed ID: 20573570
[TBL] [Abstract][Full Text] [Related]
30. Expression and activity of the efflux transporters ABCB1, ABCC2 and ABCG2 in the human colorectal carcinoma cell line LS513.
Salphati L; Plise EG; Li G
Eur J Pharm Sci; 2009 Jun; 37(3-4):463-8. PubMed ID: 19491037
[TBL] [Abstract][Full Text] [Related]
31. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
[TBL] [Abstract][Full Text] [Related]
32. Transepithelial transport of fusariotoxin nivalenol: mediation of secretion by ABC transporters.
Tep J; Videmann B; Mazallon M; Balleydier S; Cavret S; Lecoeur S
Toxicol Lett; 2007 May; 170(3):248-58. PubMed ID: 17481833
[TBL] [Abstract][Full Text] [Related]
33. Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
Merino G; Jonker JW; Wagenaar E; Pulido MM; Molina AJ; Alvarez AI; Schinkel AH
Drug Metab Dispos; 2005 May; 33(5):614-8. PubMed ID: 15703302
[TBL] [Abstract][Full Text] [Related]
34. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
Wortelboer HM; Usta M; van der Velde AE; Boersma MG; Spenkelink B; van Zanden JJ; Rietjens IM; van Bladeren PJ; Cnubben NH
Chem Res Toxicol; 2003 Dec; 16(12):1642-51. PubMed ID: 14680379
[TBL] [Abstract][Full Text] [Related]
35. Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosis.
Lubamba B; Lecourt H; Lebacq J; Lebecque P; De Jonge H; Wallemacq P; Leal T
Am J Respir Crit Care Med; 2008 Mar; 177(5):506-15. PubMed ID: 18006891
[TBL] [Abstract][Full Text] [Related]
36. Transport of glyburide by placental ABC transporters: implications in fetal drug exposure.
Gedeon C; Behravan J; Koren G; Piquette-Miller M
Placenta; 2006; 27(11-12):1096-102. PubMed ID: 16460798
[TBL] [Abstract][Full Text] [Related]
37. Regulation of expression and activity of multidrug resistance proteins MRP2 and MDR1 by estrogenic compounds in Caco-2 cells. Role in prevention of xenobiotic-induced cytotoxicity.
Arias A; Rigalli JP; Villanueva SS; Ruiz ML; Luquita MG; Perdomo VG; Vore M; Catania VA; Mottino AD
Toxicology; 2014 Jun; 320():46-55. PubMed ID: 24685904
[TBL] [Abstract][Full Text] [Related]
38. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase 5 inhibitors and cystic fibrosis: correcting chloride channel dysfunction.
Clarke LL
Am J Respir Crit Care Med; 2008 Mar; 177(5):469-70. PubMed ID: 18296466
[No Abstract] [Full Text] [Related]
40. Reversal of P-gp and BCRP-mediated MDR by tariquidar derivatives.
Li XQ; Wang L; Lei Y; Hu T; Zhang FL; Cho CH; To KK
Eur J Med Chem; 2015 Aug; 101():560-72. PubMed ID: 26197160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
